Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 60, indicating a potential upside of 55% from the current price of HKD 38.7 [2][5]. Core Insights - The commercialization of CM310 is progressing well, with satisfactory sales performance in the first quarter. The company aims to expand its commercialization team from over 300 to 500 by the end of 2025, focusing on hospital access and negotiations for insurance coverage [3]. - The next-generation dual antibody CM512 is a key product in the pipeline, with Phase 1 data expected in Q3 2025. The company is also advancing multiple overseas clinical trials, with data readouts anticipated in 2026 [4]. - The company has set a sales guidance of RMB 500 million for the year, with significant contributions expected in the second half [3]. Summary by Sections Commercialization Progress - CM310's commercialization team is currently over 300 members, with plans to expand to 500 by the end of 2025. The team is focused on increasing hospital access and engaging with dermatologists and ENT specialists [3]. - The first quarter sales performance was satisfactory, with 29 provinces already having access to CM310. The pricing strategy positions CM310 competitively against existing treatments [3]. Pipeline Development - CM512 is positioned as a next-generation long-acting autoimmune drug, with global development progress ranking second only to a competitor. The company is focusing on autoimmune and respiratory indications [4]. - The company is also initiating overseas clinical trials for several molecules, with data expected as early as next year [4][10]. Financial Projections - Revenue is projected to grow significantly, with estimates of RMB 354 million in 2023, increasing to RMB 2.249 billion by 2027, reflecting a compound annual growth rate of 46% [12][14]. - The company anticipates a net loss that narrows over the forecast period, with a projected loss of RMB 595 million by 2027 [12][14].

证 券 研 究 报 告 太古地产（01972.HK）深度研究报告 推荐（首次） 重奢运营久久为功，26 年租金有望再迎增长 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | | | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | --- | | 营业总收入(百万港元) | 14,428 | 14,616 | | | 14,995 | 18,638 | | 同比增速(%) | -2.1% | 1.3% | | | 2.6% | 24.3% | | 归母净利润(百万港元) | -766 | 2,605 | | | 4,118 | 5,679 | | 同比增速(%) | -129.0% | 440.1% | | | 58.1% | 37.9% | | 每股盈利(港元) | -0.13 | 0.45 | | | 0.71 | 0.98 | | 市盈率(倍) | -117.1 | 33.5 | | | 21.8 | 15.8 | | 市净率(倍) | 0.3 | 0.3 | | | 0.3 | 0.3 | | ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company has successfully transitioned to quality education, which is expected to support revenue growth. In 2024, it achieved a revenue of 1.1 billion HKD, representing a year-on-year increase of 125.2%. The net profit attributable to the parent company was 190 million HKD, up 110.9% year-on-year [4][6]. - The company's contract liabilities at the end of 2024 were 600 million HKD, a year-on-year increase of 184.3%, which is anticipated to support revenue growth in 2025. The introduction of AI products is expected to enhance efficiency for both teachers and students [7]. Summary by Sections Financial Performance - In 2024, the company generated revenue of 1.1 billion HKD, with segments of quality education, full-time review, and tutoring contributing 710 million, 210 million, and 180 million HKD respectively, showing year-on-year growth rates of 411.7%, 1%, and 25.2% [6]. - The net profit for 2024 was 190 million HKD, with a lower growth rate compared to revenue due to adjustments in revenue structure leading to a decline in gross margin and an increase in sales and management expense ratios [6]. Future Projections - The company is projected to achieve revenues of 2.02 billion, 2.28 billion, and 2.54 billion HKD for the years 2025, 2026, and 2027 respectively, with corresponding net profits of 320 million, 380 million, and 420 million HKD [7][8]. - The expected price-to-earnings ratios for 2025, 2026, and 2027 are 9x, 8x, and 7x respectively, indicating a favorable valuation outlook [7][8]. Market Position - The company is recognized as a leader in K12 education in South China, successfully expanding its market presence in Guangzhou, Shenzhen, and Foshan. The increasing demand for education in the Greater Bay Area is expected to enhance its competitive position [7].

丨证券研究报告丨 港股研究丨公司点评丨巨子生物（2367.HK） [Table_Title] 巨子生物 2024 年年报点评：可复美延续高增， 可丽金结构优化 报告要点 [Table_Summary] 公司公布 2024 年年报，实现收入 55.4 亿元，同比增长 57%，实现净利润 20.6 亿元，同比增 长 42%，实现经调整净利润 21.5 亿元，同比增长 46.5%。董事会建议派发末期股息每股 0.60 元，特别股息每股 0.59 元。 分析师及联系人 %% %% research.95579.com 1 [Table_Author] SAC：S0490514080004 SAC：S0490520080019 SFC：BUV258 李锦 罗祎 曾维朵 请阅读最后评级说明和重要声明 %% %% 巨子生物（2367.HK） cjzqdt11111 [Table_Title 巨子生物 2024 2] 年年报点评：可复美延续高增， 可丽金结构优化 [Table_Summary2] 事件描述 公司公布 2024 年年报，实现收入 55.4 亿元，同比增长 57%，实现归母净利润 20.6 亿元，同 比增长 42 ...

2025 年 4 月 7 日公司发布公告，2025 年 1-3 月绿城中国自投项目 取得合同销售金额约 363 亿元，绿城集团累计取得总合同销售金 额约 524 亿元。2025 年 3 月 28 日，绿城中国发布 2024 年年报， 2024 年实现营收 1585.46 亿元，同比+20.7%；实现归母净利润 15.96 亿元，同比-48.8%。 合联营企业亏损&计提减值压力，当期归母净利润下滑：得益于前 期销售均价较高的项目进入结转，公司物业销售收入保持高增。 2024 年公司物业销售收入 1470.2 亿元（占总收入 92.7%），同比 +21.9%。而归母净利润同比下滑主要因为：①合联营企业业绩亏 损，2024 年合联营企业实现亏损 6.33 亿元，同比减少 27.98 亿元； ②计提非金融资产减值和公允价值变动损失净额 49.17 亿元，同 比多计提和损失 28.82 亿元。 销售增速优于行业，核心城市销售市占率高：2024 年公司总合同 销售金额 2768 亿元，同比-8.1%，其中自投销售金额 1718 亿元， 同比-11.6%（TOP10 房企平均增速-24.4%），自投排名升至行业第 6（20 ...

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage, highlighting a value reassessment amid the PC replacement cycle [5][87]. Core Insights - The company is positioned to benefit from the ongoing PC replacement cycle, particularly as Windows 10 support ends in October 2025, which may drive demand for new devices [7][40]. - The AI transformation across its three main business segments (IDG, ISG, SSG) is expected to enhance growth and profitability [11][74]. - The report anticipates significant revenue growth in the commercial PC sector, with a projected shipment of 138 million units in 2025, reflecting a 4.3% year-on-year increase [59][60]. Summary by Sections Market Performance - The closing price of the stock is HKD 7.50, with a market capitalization of approximately HKD 93 billion [3]. Financial Forecasts and Valuation - Revenue projections for the company are as follows: - 2023: USD 61.95 billion - 2024: USD 56.86 billion - 2025E: USD 67.65 billion - 2026E: USD 74.63 billion - 2027E: USD 80.35 billion - Net profit forecasts are: - 2023: USD 1.68 billion - 2024: USD 1.10 billion - 2025E: USD 1.62 billion - 2026E: USD 1.80 billion - 2027E: USD 2.05 billion - The report indicates a projected PE ratio of 7X for 2026, which is below the average PE of comparable companies [6][87]. Business Analysis - The company operates through three main segments: - Intelligent Device Group (IDG): Contributes 69% of revenue, with a projected growth rate of 12% from 2025 to 2027. - Infrastructure Solutions Group (ISG): Accounts for 20% of revenue, with a forecasted growth of 52% in 2025. - Solutions and Services Group (SSG): Represents 11% of revenue, with expected growth of 11% in 2025 [19][21][83]. Key Growth Drivers - The report emphasizes the importance of the PC replacement cycle and the demand for AI-integrated PCs (AIPC) as significant growth drivers for the company [11][59]. - The company’s strategy includes leveraging its AI capabilities to enhance user experience and drive demand in both commercial and consumer markets [57][60]. Strategic Initiatives - The company has adopted a strategic framework called "One Horizontal and Five Verticals" to support its AI infrastructure, aiming to provide comprehensive solutions across various sectors [74]. - The SSG segment focuses on local market needs, enhancing its service offerings to meet the demands of various industries [80].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 60, indicating a potential upside of 55% from the current price of HKD 38.7 [2][5]. Core Insights - The commercialization of CM310 is progressing well, with satisfactory sales performance in the first quarter. The company aims to expand its commercialization team from over 300 to 500 by the end of 2025, focusing on hospital access and negotiations for insurance coverage [3]. - The next-generation dual antibody CM512 is a key product in the research pipeline, with Phase 1 data expected in Q3 2025. The company is also advancing overseas clinical trials for several molecules, with data expected in 2026 [4][10]. - The company has set a sales guidance of RMB 500 million for the year, with significant contributions expected in the second half [3]. Summary by Sections Commercialization Progress - CM310's commercialization team is currently over 300 members, with plans to expand to 500 by the end of 2025. The team is focused on increasing hospital access and engaging with dermatologists and ENT specialists [3]. - The first quarter sales performance was satisfactory, with 29 provinces already having access to CM310. The pricing strategy positions CM310 competitively against existing treatments [3]. Research and Development - CM512, targeting TSLP and IL-13, is in the second position globally for development. The company is focusing on autoimmune and respiratory indications, with ongoing trials in China and plans for international trials [4][10]. - The company anticipates multiple overseas data readouts in 2026, including for CM901 and CM336 [10]. Financial Projections - Revenue is projected to grow significantly, with estimates of RMB 354 million in 2023, increasing to RMB 2.249 billion by 2027, reflecting a compound annual growth rate of 46% [12][14]. - The company expects to incur losses in the coming years, with net losses projected to peak at RMB 737 million in 2026 before improving [12][14].

证券研究报告 医药生物 | 生物制品 港股|公司点评报告 hyzqdatemark 2025 年 04 月 10 日 | 基本数据 | 2025 | 年 04 | 月 | 09 | 日 | | --- | --- | --- | --- | --- | --- | | 收盘价（港元） | | | | 42.20 | | | 一年内最高/最低（港 | | | 52.15/28.65 | | | | 元） | | | | | | | 总市值（百万港元） | | | | 69,552.86 | | | 流通市值（百万港元） | | | | 69,552.86 | | | 资产负债率（%） | | | | 39.28 | | | 资料来源：聚源数据 | | | | | | 信达生物(01801.HK) 投资评级： 买入（维持） ——超预期实现盈利，全球化布局加速推进 投资要点： 风险提示：竞争格局恶化风险、销售不及预期风险、行业政策风险等。 | 盈利预测与估值（人民币） | | | | | | | --- | --- | --- | --- | --- | --- | | | 2023 | 2024 | 2025E ...

Investment Rating - The investment rating for the company is Neutral with a target price of HKD 16.25, indicating a potential upside of 11.9% from the current closing price of HKD 14.52 [2][7]. Core Insights - The company is expected to maintain stable revenue and gross margin performance in 2025, with a projected revenue of RMB 29,080 million, reflecting a year-on-year growth of 1.4% [3][6]. - The management anticipates that the gross margin will remain stable or slightly improve, supported by product mix optimization and operational cost management [7][8]. - The running category has shown significant growth, with retail sales increasing by 25% and total sales of the three core IPs exceeding 10.6 million pairs [7][8]. Financial Overview - Revenue for 2024 is projected at RMB 28,676 million, a 3.9% increase from 2023, with footwear sales contributing RMB 14,300 million, up 7% [6][8]. - The net profit for 2024 is expected to be RMB 3,013 million, with a net profit margin of 10.5% [6][8]. - The company plans to maintain a dividend payout ratio of 50%, increasing the dividend per share to RMB 0.5848 [7][8]. Operational Performance - The company has successfully optimized its channels, closing 83 inefficient stores while increasing the number of Li Ning YOUNG stores by 40 [7][8]. - E-commerce revenue has increased, now accounting for 31% of total revenue, highlighting its role as a key growth driver [7][8]. - The company aims to strengthen its leading position in the running category while nurturing emerging categories such as outdoor and tennis [7][8]. Financial Projections - The projected financials for the next few years include: - Revenue: RMB 29,080 million in 2025, RMB 30,809 million in 2026, and RMB 32,855 million in 2027 [6][13]. - Net profit: RMB 2,971 million in 2025, RMB 3,375 million in 2026, and RMB 3,871 million in 2027 [6][13]. - The company’s gross margin is expected to be 49.5% in 2025, with a slight increase to 50% by 2027 [14].

证券研究报告 | 2025年04月10日 资料来源：Wind、国信证券经济研究所预测 注：摊薄每股收益按最新总股本计算 绿城管理控股（09979.HK） 优于大市 竞争加剧导致业绩承压 归母净利-18%，政府代建承压。2024 年公司实现营业收入 34 亿元，同比增 长 4%；实现归母净利润 8 亿元，同比下降 18%。公司增收不增利的原因主要 为毛利率下滑，以及计提信贷减值约 1 亿元。分类别看，公司商业代建收入 为 28 亿元，同比增长 17%,收入占比增长 9pct 至 80%；政府代建业务收入 6.3 亿元，同比下降21%。2024 年公司整体毛利率为49.6%，较上年末下降2.6pct， 其中商业代建毛利率为 51%，政府代建毛利率为 40%，分别较上年末下降 1、 5pct。 规模稳中有进，新拓结构优化。截至 2024 年末，公司业务分布已覆盖 130 个城市，合约总建筑面积达 1.3 亿平方米，同比增长 5%，当期在建面积 0.5 亿平放米，同比增长 3%，保持行业龙头地位。在全国化布局下，公司市占率 稳步扩大，2024 年新签代建规模 3649 万平方米，新签市占率 22.1%，较上 年提升 ...